Want to join the conversation?
$MYL, the biggest U.S. generic drug maker, said that with the Biocon partnership and Momenta collaboration, it now has a combined portfolio of 15 biosimilar and insulin analog generic products in development with a current total brand market value of more than $75Bil in worldwide sales.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.